MedTrace Logo

The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia

NCT02236741 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26814

Last updated 2014-09-11

No results posted yet for this study

Summary

Study to assess the risk of incident heart failure associated with the use of pramipexole compared with other dopamine agonists and additionally, to assess the risk of incident heart failure associated with the use of dopamine agonists in comparison with no use of dopamine agonist therapy

Conditions

Interventions

DRUG

Mirapexin® (Sifrol®)

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02236741 on ClinicalTrials.gov